Press Releases

Shanghai, China, 
April 10, 2025

WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, announced that it has successfully achieved ISO 22301:2019 Business Continuity Management System (BCMS) certification. The certification underscores the company’s commitment to excellence in strengthening operational resilience, while demonstrating its dedication to enhancing risk management capabilities, and providing world-class solutions to clients globally.
 

 
ISO 22301 is an internationally recognized standard for BCMS. It offers a structured framework to help organizations identify critical business activities and resources, evaluate potential risks, develop effective response strategies, and maintain operations and ensure service delivery, even in unforeseen circumstances. By adopting and optimizing its BCMS in alignment with this standard, WuXi XDC has further heightened its ability to safeguard operations, protect stakeholder interests, and deliver continuous, uninterrupted services.
 
Dr. Jimmy Li, CEO of WuXi XDC, stated, “This ISO 22301 certification underscores WuXi XDC’s attainment of internationally recognized high standards in ensuring business continuity, enhancing organizational resilience, and protecting critical business processes. As a leading global CRDMO focused on the bioconjugate market, WuXi XDC offers our global partners integrated services from research and development to manufacturing, by establishing an extensive risk prevention and control system as well as a robust information security protection network. Looking ahead, WuXi XDC will further enhance business continuity management capabilities by adhering to the standardized processes outlined in the certification system, continuously improving response efficiency and service quality, and accelerating the R&D breakthroughs and clinical transformation of innovative therapies.”
 
About WuXi XDC
WuXi XDC Cayman Inc.  (“WuXi XDC” or the “Company”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com.
 
WuXi XDC Contacts
Investor：wuxixdc.ir@wuxibiologics.com

Media：wuxixdc_pr@wuxibiologics.com

BD：wuxixdc_info@wuxibiologics.com